Riboflavin (B2) production

Gut bacteria differ in their ability to make vitamin B2. Stool DNA sequencing can estimate how much of that vitamin-making potential your microbial community carries. Studies have linked differences in this potential with insulin resistance and several diseases, but they haven't established that the result predicts your future health.

This is a research-stage measurement. There are no validated clinical cutpoints or treatment targets, and no trial has shown that using this score to guide care improves health outcomes.

What the Result Represents

Your body can't make riboflavin. Dietary riboflavin is absorbed mainly in the small intestine, while some bacteria farther down in the colon can produce it. The amount that microbial production contributes to your nutritional needs remains uncertain.

This test uses shotgun metagenomic sequencing to examine microbial DNA in stool and estimate riboflavin-building potential. It describes the community's genetic capabilities. Actual vitamin production also depends on whether those genes are active and on conditions inside the gut.

In a survey of 256 common gut bacterial genomes, about 65% were predicted to contain the machinery needed to make riboflavin. That percentage describes the selected genomes studied; it isn't the proportion of your vitamin supply made by bacteria.

Why Bacteria Use This Vitamin

Some bacteria make riboflavin, while others obtain it from their surroundings. Laboratory work on the A2-165 strain historically classified as Faecalibacterium prausnitzii found that it requires an outside supply. Bacteria in this group produce butyrate. Butyrate is a fatty acid that cells lining the colon use as fuel. Findings from a particular strain don't establish the requirements of every related bacterium in your gut.

Laboratory experiments also show that compounds formed during microbial riboflavin synthesis can activate certain immune cells. This helps explain scientific interest in the pathway, but a stool gene score hasn't been validated as a measure of immune function.

Blood Sugar and Inflammation

In Dutch adults in the Lifelines-DEEP study, greater microbial riboflavin-building potential was associated with lower fasting insulin, less insulin resistance, and lower C-reactive protein. The study measured participants at one point in time. It didn't show that this microbial function prevents diabetes or that changing it lowers inflammation.

The association isn't consistent across every population. A separate analysis found no significant difference in riboflavin-related gene abundance between Chinese participants with and without type 2 diabetes. These studies describe group patterns, without establishing how accurately the measurement identifies a metabolic problem in an individual.

Lung Disease

A study compared adults with stable chronic obstructive pulmonary disease with healthy controls. Chronic obstructive pulmonary disease includes emphysema and chronic bronchitis. The disease group had lower abundance of gut microbial riboflavin-related pathways and lower serum riboflavin measured separately.

The stool analysis measured genetic potential, while the serum analysis measured the vitamin itself. Smoking history and other characteristics differed between the groups. The study can't establish whether altered microbial production contributed to lung disease, resulted from it, or reflected those other differences.

Parkinson's Disease

An analysis pooling stool-sequencing datasets from Japan, the United States, Germany, China, and Taiwan found fewer microbial genes for making riboflavin and biotin in people with Parkinson's disease. Faecalibacterium prausnitzii was also less abundant across the datasets.

The researchers proposed that reduced vitamin production could contribute to changes in gut fatty acids and the protective mucus layer. That sequence remains a hypothesis. The study didn't establish that these changes precede Parkinson's disease or that this score can be used to screen for it.

Gum Disease and the Gut

A small study of advanced periodontitis found differences in vitamin-building pathways in both saliva and stool. Periodontitis damages the tissues supporting your teeth. Riboflavin-related functions were among the pathways associated with the healthier microbial profiles. The findings connect oral and gut microbial patterns, but they don't establish a stool-based diagnosis of gum disease.

Age, Sex, and Population Differences

A Dutch study comparing children with adults predicted greater riboflavin-building capacity in children. It inferred microbial functions from a bacterial identification method called 16S sequencing. That differs from the whole-genome sequencing used here, so the study's predicted values aren't directly interchangeable with this result.

Research has also described differences by sex and between populations. Such differences don't establish that a particular age group, sex, or population is vitamin deficient, and they haven't produced validated targets for this score.

Gut Production and Your Body's Supply

Microbial production potential and your nutritional status are separate questions. Your cells use riboflavin to make molecules needed for energy production and other chemical reactions. Deficiency can cause cracks at the corners of the mouth, a sore tongue, and anemia, though these symptoms have other causes too.

In a study of young women in Vancouver, a substantial minority met the study's biochemical definition of deficiency while far fewer reported dietary intake below the estimated requirement. The researchers used a functional red blood cell enzyme assay called EGRAC. They did not diagnose deficiency from a circulating riboflavin concentration or a stool pathway score, and this selected sample doesn't establish how common deficiency is in the wider population.

When Results Can Be Misleading

• Genetic potential versus actual production: DNA can show that vitamin-building machinery is present without showing how much vitamin it produces or how much you absorb.
• Relative abundance: A pathway can become a larger share of the microbial profile because other organisms declined. That doesn't necessarily mean more vitamin is being made.
• Recent changes in the gut: Antibiotics, bowel preparation, gastrointestinal infections, diet changes, and changes in bowel transit can alter the microbial community.
• Laboratory differences: DNA extraction, sequencing depth, reference databases, and analysis software affect functional estimates. Values from different methods or laboratories aren't directly interchangeable.
• Collection and storage: Contamination, incorrect preservation, or shipping outside the collection instructions can change the profile.

What a Change in the Score Means

A change can describe a shift in your microbial community, but its health meaning remains uncertain. Neither a higher score nor a stable score has been shown to be an outcome worth targeting. Personal trends also include biological and measurement variation.